{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Flets-talk-about-sact-7ac1b632.simplecast.com%2Fepisodes%2Flets-talk-about-inavo120-7_uQtlcP","width":444,"version":"1.0","type":"rich","title":"Let's Talk About INAVO120","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/2db546c4-2aeb-4ca5-9056-8011a722c013/86a2a8ff-e3cd-43f8-9caf-9fa80e59326f/lets-talk-about-sact-logo-final-black-square.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/0f66e669-78aa-4168-a9d2-5733b943a84a\" height=\"200\" width=\"100%\" title=\"Let&apos;s Talk About INAVO120\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode we are joined by Suzanne Frank. We discuss Inavo120 (Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer) study. We discuss the relevance of the data and how it might change practice going forward. This study is available to read at https://www.nejm.org/doi/full/10.1056/NEJMoa2404625 and the update at https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.1003"}